

Connecting via Winsock to STN

Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:sssptal645vlf
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files
NEWS 3 Feb 06 Engineering Information Encompass files have new names
NEWS 4 Feb 16 TOXLINE no longer being updated
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7 May 07 DGENE Reload
NEWS 8 Jun 20 Published patent applications (A1) are now in USPATFULL
NEWS 9 JUL 13 New SDI alert frequency now available in Derwent's
DWPI and DPCI

NEWS EXPRESS July 11 CURRENT WINDOWS VERSION IS V6.0b,
CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2001
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:18:58 ON 07 AUG 2001

=> FIL EUROPATFULL
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.15	0.15

FULL ESTIMATED COST

FILE 'EUROPATFULL' ENTERED AT 16:19:15 ON 07 AUG 2001
COPYRIGHT (c) 2001 WILA Verlag Muenchen (WILA)

FILE LAST UPDATED: 02 AUG 2001 <20010802/UP>
MOST RECENT EPO WEEK: 200130 <200130/EW>
FILE COVERS 1987 TO DATE

=> s GLP-1 and insulin
144 GLP
3 GLPS
146 GLP

(GLP OR GLPS)
698927 1
42 GLP-1
(GLP(W)1)
4248 INSULIN
144 INSULINS
4257 INSULIN
(INSULIN OR INSULINS)
L1 38 GLP-1 AND INSULIN

=> d bib ab 1-38

L1 ANSWER 1 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 1106702 EUROPATFULL ED 20010622 EW 200124 FS OS
TIEN High-throughput screening of compounds using electrospray ionization
mass spectrometry (ESI-MS).
TIDE Screeningverfahren mit hohem Durchsatz (High-throughput screening = HTS)
von Verbindungen mittels Elektrospray-ionisation Massenspektrometrie
(ESI-MS).
TIFR High-throughput screening of compounds using electrospray ionization
mass spectrometry (ESI-MS).
IN Greig, Michael James, 1570 Martingale Court, Carlsbad, California 92009,
US;
Robinson, Jessica Marie, 6809 Camino De Amigos, Carlsbad, California
92009, US
PA AGOURON PHARMACEUTICALS, INC., 10350 North Torrey Pines Road, La Jolla,
CA 92037-1020, US
PAN 1487846
AG Hofmann, Harald et al., Sonnenberg Fortmann, Patent- und Rechtsanwaelte,
Herzogspitalstrasse 10, 80331 Muenchen, DE
AGN 157101
OS BEPA2001044 EP 1106702 A1 0029
SO Wila-EPZ-2001-H24-T1a
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE;
R IT; R LI; R LU; R MC; R NL; R PT; R SE; R TR; R AL; R LT; R LV; R MK;
R RO; R SI
PIT EPA1 EUROPAEISCHE PATENTANMELDUNG
PI EP 1106702 A1 20010613
OD 20010613
AI EP 2000-126229 20001130
PRAI US 1999-169552 19991208
US 2000-521106 20000307
ABEN A high-throughput screening system employing electrospray ionization
mass spectrometry (ESI-MS) to investigate the interactions of between
small molecules and polynucleotides and monitor small
molecule:polynucleotide complexes, thereby allowing valid mechanistic
interactors to be distinguished from false positive signals. ESI-MS may
also be used as an early-stage toxicity screening tool.

L1 ANSWER 2 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 1099701 EUROPATFULL ED 20010529 EW 200120 FS OS
TIEN 7-((4'-Trifluoromethyl-biphenyl-2-carbonyl)amino)-quinoline-3-carboxylic
acid amides, and methods of inhibiting the secretion of apolipoprotein
B.
TIDE 7-((4'-Trifluoromethyl-biphenyl-2-carbonyl)amino)-chinolin-3-

carbonsaeure Amide, und Methoden zur Inhibierung von Apolipoprotein B Sekretion.

TIFR 7-((4'-Trifluoromethyl-biphenyl-2-carbonyl)amino)-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B.

IN Bertinato, Peter, Pfizer Global Research, and Development, Estern Point Road, Groton, Connecticut 06340, US;
Hamanaka, Ernest Seiichi, Pfizer Global Research, and Development, Estern Point Road, Groton, Connecticut 06340, US;
Ruggeri, Roger Benjamin, Pfizer Global Research, and Development, Estern Point Road, Groton, Connecticut 06340, US;
Wilson, Douglas Paul, Pfizer Global Research, and Development, Estern Point Road, Groton, Connecticut 06340, US

PA Pfizer Products Inc., Eastern Point Road, Groton, Connecticut 06340, US

PAN 2434221

AG McMunn, Watson Palmer et al., Pfizer Limited Patents Department Ramsgate Road, Sandwich, Kent CT13 9NJ, GB

AGN 72194

OS BEPA2001037 EP 1099701 A1 0124

SO Wila-EPZ-2001-H20-T1a

DT Patent

LA Anmeldung in Englisch; Veroeffentlichung in Englisch

DS R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R TR; R AL; R LT; R LV; R MK; R RO; R SI

PIT EPA1 EUROPÄISCHE PATENTANMELDUNG

PI EP 1099701 A1 20010516

OD 20010516

AI EP 2000-309947 20001109

PRAI US 1999-164803 19991110

US 2000-224956 20000811

ABEN This invention relates to compounds of Formula I <image> that inhibit the secretion of apolipoprotein B, to pharmaceutical compositions comprising the compounds, and to methods of treating and/or preventing atherosclerosis, obesity, diabetes, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia, pancreatitis, myocardial infarction, stroke, restenosis, or Syndrome X. This invention also relates to methods of reducing the secretion of apolipoprotein B and/or inhibiting microsomal triglyceride transfer protein.

L1 ANSWER 3 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 1092711 EUROPATFULL ED 20010426 EW 200116 FS OS

TIEN RETINOID-ASSOCIATED RECEPTOR REGULATORS.

TIDE RETINOIDASSOZIIERTE REGULATOREN VON REZEPTOREN.




TIFR REGULATEURS DU RECEPTEUR ASSOCIE AUX RETINOIDES.

IN SUGIYAMA, Yasuo, 7-2 Daiwahigashi 5-chome, Kawanishi-shi, Hyogo 666-0111, JP;
MOMOSE, Yu, 2-1-213 Sumiregaoka 3-chome, Takarazuka-shi, Hyogo 665-0847, JP;
KIMURA, Hiroyuki, 2-20-808 Oohamanakamachi 1-cho, Sakai-shi, Osaka 590-0000, JP;
SAKAMOTO, Junichi, Fureguransu A103, 14-30 Kamishinden 1-chome, Toyonaka-shi, Osaka 565-0085, JP;
ODAKA, Hiroyuki, 12-12 Katsuragi 2-chome, Kita-ku, Kobe-shi, Hyogo 651-1223, JP

PA Takeda Chemical Industries, Ltd., 1-1 Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0045, JP

PAN 204702

AG Caffin, Lee et al., Takeda Euro Patent Office, 10 Charles II Street,

London SW1Y 4AA, GB
 AGN 62327
 OS BEPA2001029 EP 1092711 A1 0080
 SO Wila-EPZ-2001-H16-T1a
 DT Patent
 LA Anmeldung in Japanisch; Veroeffentlichung in Englisch;
 Verfahren in Englisch
 DS R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE;
 R IT; R LI; R LU; R MC; R NL; R PT; R SE
 PIT EPA1 EUROPÄISCHE PATENTANMELDUNG (Internationale Anmeldung)
 PI EP 1092711 A1 20010418
 OD 20010418
 AI EP 1999-926853 19990630
 PRAI JP 1998-186698 19980701
 RLI WO 99-JP3520 990630 INTAKZ
 WO 0001679 000113 INTPNR
 ABEN A pharmaceutical composition of the invention which is a
 retinoid-related receptor function regulating agent comprising a
 1,3-azole derivative represented by formula (I):  wherein
 R.sup1. is an aromatic hydrocarbon group or an aromatic heterocyclic
 group, each of which may be substituted; R.sup2. is hydrogen or an
 optionally substituted hydrocarbon group; X is O, S or a group
 represented by the formula: -NR.sup4.- wherein R.sup4. is hydrogen or an
 optionally substituted alkyl group; A is an aromatic hydrocarbon group
 or an aromatic heterocyclic group, each of which may be substituted;
 R.sup3. is a group represented by the formula: -OR.sup5. wherein R.sup5.
 is hydrogen or an optionally substituted hydrocarbon group, or
 -NR.sup6.R.sup7. wherein R.sup6. and R.sup7. are same or different and
 each is hydrogen or an optionally substituted hydrocarbon group, or
 R.sup6. and R.sup7. may be taken together with an adjacent nitrogen atom
 to form a ring, provided that compounds represented by the formulae:
  are excluded, or its salt, is low in toxicity, and
 can be employed, for instance, as an agent for preventing or treating
 diabetes (e.g., **insulin**-dependent diabetes, non-
insulin-dependent diabetes, gestational diabetes), an agent for
 preventing or treating hyperlipidemia (e.g., hypertriglyceridemia,
 hypercholesterolemia, hypo-HDL-cholesterolemia), an **insulin**
 sensitivity enhancing agent, an **insulin** resistance improving
 agent, an agent for preventing or treating impaired glucose tolerance
 (IGT), and an agent for preventing transition from impaired glucose
 tolerance to diabetes.

Further, a pharmaceutical composition of the invention can be used, for
 instance, as an agent for preventing or treating diabetic complications
 (e.g., neuropathy, nephropathy, retinopathy, cataract, macroangiopathy,
 osteopenia), obesity, osteoporosis, cachexia (e.g., carcinomatous
 cachexia, tuberculous cachexia, diabetic cachexia, hemopathic cachexia,
 endocrinopathic cachexia, infectious cachexia or cachexia induced by
 acquired immunodeficiency syndrome), fatty liver, hypertension,
 polycystic ovary syndrome, renal diseases (e.g., diabetic nephropathy,
 glomerular nephritis, glomerulosclerosis, nephrotic syndrome,
 hypertensive nephrosclerosis, terminal renal disorder), muscular
 dystrophy, myocardial infarction, angina pectoris, cerebral infarction,
insulin resistant syndrome, syndrome X, hyperinsulinemia-induced
 sensory disorder, tumor (e.g., leukemia, breast cancer, prostate cancer,
 skin cancer), arteriosclerosis (e.g., atherosclerosis) and as a
 pharmaceutical for controlling appetite or food intake.

L1 ANSWER 4 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 1088824 EUROPATFULL ED 20010417 EW 200114 FS OS

TIEN Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors.
 TIDE Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren.
 TIFR Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors.
 IN Joe, Daisy, 1180 Welch Road, Apt. 821, Palo Alto, California 94304, US
 PA Pfizer Products Inc., Eastern Point Road, Groton, Connecticut 06340, US
 PAN 2434221
 AG Motion, Keith Robert et al., Pfizer Limited Patents Department Ramsgate Road, Sandwich, Kent CT13 9NJ, GB
 AGN 91141
 OS BEPA2001025 EP 1088824 A2 0073
 SO Wila-EPZ-2001-H14-T1a
 DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO; R SI
 PIT EPA2 EUROPÄISCHE PATENTANMELDUNG
 PI EP 1088824 A2 20010404
 OD 20010404
 AI EP 2000-308131 20000918
 PRAI US 1999-157148 19990930
 ABEN This invention relates to compounds of Formula I <image> or stereoisomers, pharmaceutically acceptable salts or prodrugs thereof or a pharmaceutically acceptable salts of the prodrugs. This invention also relates to pharmaceutical compositions comprising a compound of Formula I, and to methods of treatment of diabetes, **insulin** resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, or tissue ischemia.

L1 ANSWER 5 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 1088819 EUROPATFULL ED 20010417 EW 200114 FS OS
 TIEN 6-azauracil derivatives as thyroid receptor ligands.
 TIDE 6-Azaauracilderivate als Liganden der Thyroidrezeptoren.
 TIFR 6-azauracil derivatives as thyroid receptor ligands.
 IN Dow, Robert Lee, Pfizer Central Res., Eastern Point Road, Groton, Connecticut 06340, US;
 Chiang, Yuan-Ching Phoebe, Pfizer Central Res., Eastern Point Road, Groton, Connecticut 06340, US;
 Estep, Kimberly Gail, Pfizer Central Res., Eastern Point Road, Groton, Connecticut 06340, US
 PA Pfizer Products Inc., Eastern Point Road, Groton, Connecticut 06340, US
 PAN 2434221
 AG Wood, David John et al., PFIZER LIMITED, European Patents Department, Ramsgate Road,, Sandwich, Kent CT13 9NJ, GB
 AGN 37882
 OS BEPA2001025 EP 1088819 A2 0155
 SO Wila-EPZ-2001-H14-T1a
 DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO; R SI
 PIT EPA2 EUROPÄISCHE PATENTANMELDUNG
 PI EP 1088819 A2 20010404
 OD 20010404
 AI EP 2000-308112 20000918
 PRAI US 1999-156842 19990930
 ABEN The present invention provides novel compounds of the Formula I <image>

and prodrugs thereof, geometric and optical isomers thereof, and pharmaceutically acceptable salts of such compounds, prodrugs and isomers, wherein R.sup1. to R.sup8. and W are as described herein. Pharmaceutical compositions containing such compounds, prodrugs, isomers or pharmaceutically acceptable salts thereof, and methods, pharmaceutical compositions and kits for treating obesity, overweight condition, hyperlipidemia, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesterolemia, depression, osteoporosis, cardiac arrhythmias, glaucoma and congestive heart failure are also provided.

L1 ANSWER 6 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 1084705 EUROPATFULL ED 20010330 EW 200112 FS OS
 TIEN Method for lowering blood glucose levels in mammals.
 TIDE Verfahren zur Senkung des Blutglukosespiegels in Saeugern.
 TIFR Method for lowering blood glucose levels in mammals.
 IN Demuth, Hans-Ulrich, Hegelstrasse 14, 06114 Halle, DE;
 Rosche, Fred, Benndorfer Strasse 18a, 06184 Dieskau, DE;
 Schmidt, Joern, Eichendorffstrasse 2, 06114 Halle, DE;
 Pauly, Robert P., 2631 Fairview Crescent, Vancouver, B.C. V6T 2B8, CA;
 McIntosh, Christopher H.S., 605-2233 Allison Road, Vancouver, B.C. V6T 1T7, CA;
 Pederson, Ray A., 3876 West 23rd Avenue, Vancouver, B.C. V6S 1K9, CA
 PA Probiodrug Gesellschaft fuer Arzneimittelforschung mbH, Weinbergweg 22, Biozentrum, 06120 Halle/Saale, DE
 PAN 2476601
 AG Forstmeyer, Dietmar, Dr. rer. nat., Dipl.-Chem. et al., Boeters & Bauer, Bereiteranger 15, 81541 Muenchen, DE
 AGN 77023
 OS BEPA2001021 EP 1084705 A2 0009
 SO Wila-EPZ-2001-H12-T1b
 DT Patent
 LA Anmeldung in Deutsch; Veroeffentlichung in Deutsch
 DS R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R RO; R SI
 PIT EPA2 EUROPAEISCHE PATENTANMELDUNG
 PI EP 1084705 A2 20010321
 OD 20010321
 AI EP 2000-119496 19970424
 PRAI DE 1996-19616486 19960425
 RLI EP 896538 DIV

L1 ANSWER 7 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 1076097 EUROPATFULL ED 20010228 EW 200107 FS OS
 TIEN METHOD FOR CONTROLLING CLEAVAGE BY OmpT PROTEASE.
 TIDE VERFAHREN ZUR KONTROLLE DER SPALTUNG MIT OMPT PROTEASE.
 TIFR PROCEDE DE CONTROLE DE CLIVAGE PAR LA PROTEASE DE L'OMPT.
 IN OKUNO, Kazuaki, 1830-1-102, Kitamarushima-cho, Tatebayashi-shi, Gumma 374-0057, JP;
 YABUTA, Masayuki, 743-88, Nishimisono-cho, Tatebayashi-shi, Gumma 374-0038, JP;
 OHSUYE, Kazuhiro, 243, Takara-cho, Ohta-shi, Gumma 373-0042, JP
 PA SUNTORY LIMITED, 1-40, Dojimahama 2-chome, Kita-ku, Osaka-shi, Osaka 530-8203, JP
 PAN 423902
 AG HOFFMANN - EITLE, Patent- und Rechtsanwaelte Arabellastrasse 4, 81925

Muenchen, DE
AGN 101511
OS BEPA2001013 EP 1076097 A1 0068
SO Wila-EPZ-2001-H07-T1a
DT Patent
LA Anmeldung in Japanisch; Veroeffentlichung in Englisch;
Verfahren in Englisch
DS R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE;
R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO;
R SI
PIT EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale Anmeldung)
PI EP 1076097 A1 20010214
OD 20010214
AI EP 1990-6696 20000303
PRAI JP 1999-57731 19990304
RLI WO 00-JP1309 000303 INTAKZ
WO 0052193 000908 INTPNR
ABEN By clarifying the properties of OmpT protease, a novel use thereof as a
protease and a novel method of producing a target polypeptide are
provided. More particularly, the present invention relates to a method
of controlling cleavage of a polypeptide by OmpT protease which
comprises converting a sequence site consisting of two arbitrary
consecutive amino acids and/or amino acid(s) in the vicinity of said
site in said polypeptide into other amino acids, characterized by (1)
setting lysine or arginine as the amino acid at the -1-position
concerning said site and setting a specific amino acid as the amino acid
at the +1-position; and/or (2) setting specific amino acid(s) as the
amino acid(s) at the -4-position and/or the -6-position relative to said
site; so that desired parts of said polypeptide are cleaved by OmpT
protease and/or undesired parts of said polypeptide are not cleaved by
ompT protease. For example, the present invention provides a method of
treating by OmpT protease a fusion protein having an amino acid sequence
wherein the amino acid at the +1-position is X (wherein X is an amino
acid other than glutamic acid, aspartic acid or proline); and a method
of controlling cleavage by converting the amino acids at the -6-position
and the -4-position concerning the cleavage site into amino acids other
than acidic amino acids.

L1 ANSWER 8 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 1076066 EUROPATFULL ED 20010228 EW 200107 FS OS
TIEN Peptides for lowering blood glucose levels.
TIDE Peptide zur Senkung des Blutglukosespiegels.
TIFR Peptides for lowering blood glucose levels.
IN Larsen, Bjarne Due, Arildsgard 5, 1.th., DK-2700 Broenshoej, DK;
Mikkelsen, Jens Damsgaard, Borgevej 9, DK-2800 Lyngby, DK
PA Zealand Pharmaceuticals A/S, Smedeland 26B, 2600 Glostrup, DK
PAN 2757571
OS BEPA2001013 EP 1076066 A1 0072
SO Wila-EPZ-2001-H07-T1a
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE;
R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO;
R SI
PIT EPA1 EUROPAEISCHE PATENTANMELDUNG
PI EP 1076066 A1 20010214
OD 20010214
AI EP 1999-610043 19990809
ABEN The present invention relates to novel variants that lower blood glucose
levels, specific variants of exendin-4. The invention further relates to

peptide conjugates that lower blood glucose levels and which have increased bioavailability.

L1 ANSWER 9 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 1059354 EUROPATFULL ED 20001224 EW 200050 FS OS
TIEN Sequence-determined DNA fragments and corresponding polypeptides encoded thereby.
TIDE DNS-fragmente mit bestimmter Sequenz und die dadurch kodierte Polypeptide.
TIFR Fragments d'ADN avec des sequences determinees et polypeptides encodees par lesdits fragments.
IN Alexandrov, Nickolai, 1404 Oak Trail St., Thousand Oaks, CA 91320, US; Troukhan, Maxim E., 1675 Amberwood Dr. No. 2, South Pasadena, CA 91030, US
PA Ceres Incorporated, 3007 Malibu Canyon Road, Malibu, CA 90265, US
PAN 2967260
AG Bannerman, David Gardner et al., Withers & Rogers, Goldings House, 2 Hays Lane, London SE1 2HW, GB
AGN 28001
OS BEPA2000096 EP 1059354 A2 0418
SO Wila-EPZ-2000-H50-T1a
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO; R SI
PIT EPA2 EUROPAEISCHE PATENTANMELDUNG
PI EP 1059354 A2 20001213
OD 20001213
AI EP 2000-304943 20000612
PRAI US 1999-138540 19990610
US 1999-138847 19990610
ABEN The present invention provides DNA molecules that constitute fragments of the genome of a plant, and polypeptides encoded thereby. The DNA molecules are useful for specifying a gene product in cells, either as a promoter or as a protein coding sequence or as an UTR or as a 3' termination sequence, and are also useful in controlling the behavior of a gene in the chromosome, in controlling the expression of a gene or as tools for genetic mapping, recognizing or isolating identical or related DNA fragments, or identification of a particular individual organism, or for clustering of a group of organisms with a common trait.

L1 ANSWER 10 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 997151 EUROPATFULL ED 20000514 EW 200018 FS OS
TIEN Method for administering insulinotropic peptides.
TIDE Methode zur Verabreichung von Peptiden mit insulinotroper Wirkung.
TIFR Methode d'administration de peptides a activite insulinotropique.
IN Hughes, Benjamin Lee, 402 Blue Ridge Road, Indianapolis, Indiana 46208, US;
Wolff, Ronald Keith, 12329 Brookshire Parway, Carmel, Indiana 46033, US
PA ELI LILLY AND COMPANY, Lilly Corporate Center, Indianapolis, Indiana 46285, US
PAN 204942
AG Denholm, Anna Marie et al., Eli Lilly and Company Limited, Lilly Research Center, Erl Wood Manor, Windlesham, Surrey GU20 6PH, GB
AGN 78622

OS BEPA2000033 EP 0997151 A2 0014
 SO Wila-EPZ-2000-H18-T1b
 DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE;
 R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO;
 R SI
 PIT EPA2 EUROPÄISCHE PATENTANMELDUNG
 PI EP 997151 A2 20000503
 OD 20000503
 AI EP 1999-306733 19990825
 PRAI US 1998-98273 19980828
 US 1998-100012 19980911
 ABEN The claimed invention relates to a method of administering glucagon-like
 peptide-1 molecules by inhalation, a method for treating diabetes by
 administering glucagon-like peptide-1 molecules by inhalation, and a
 method for treating hyperglycemia by administering glucagon-like
 peptide-1 molecules by inhalation.

L1 ANSWER 11 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 995440 EUROPATFULL ED 20000507 EW 200017 FS OS
 TIEN Method to increase the blood, glucose level in mammals.
 TIDE Verfahren zur Stieigerung des Blutglukosespiegels in Saeugern.
 TIFR Procède pour augmenter le taux de glucose dans le sang des mammiferes.
 IN Demuth, Hans-Ulrich, Dr., Weinbergweg 22, 06120 Halle/Saale, DE;
 Hoffmann, Torsten, Dr., Weinbergweg 22, 06120 Halle/Saale, DE;
 Kuehn-Wache, Kerstin, Weinbergweg 22, 06120 Halle/Saale, DE;
 Rosche, Fred, Dr., Weinbergweg 22, 06120 Halle/Saale, DE
 PA Probiodrug Gesellschaft fuer Arzneimittelforschung mbH, Weinbergweg 23,
 06120 Halle/Saale, DE
 PAN 2476600
 AG Forstmeyer, Dietmar, Dr. rer. nat., Dipl.-Chem. et al., Boeters & Bauer,
 Bereiteranger 15, 81541 Muenchen, DE
 AGN 77023
 OS BEPA2000030 EP 0995440 A1 0013
 SO Wila-EPZ-2000-H17-T1b
 DT Patent
 LA Anmeldung in Deutsch; Veroeffentlichung in Deutsch
 DS R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE;
 R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO;
 R SI
 PIT EPA1 EUROPÄISCHE PATENTANMELDUNG
 PI EP 995440 A1 20000426
 OD 20000426
 AI EP 1999-115236 19990802
 PRAI DE 1998-19834591 19980731

L1 ANSWER 12 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 979872 EUROPATFULL ED 20000305 EW 200007 FS OS
 TIEN Animal model for the development and therapy of diabetes mellitus.
 TIDE Tiermodell zur Entstehung und Therapie von Diabetes Mellitus.
 TIFR Animal modele pour le developement et la therapie du diabete mellitus.
 IN Peters, Heiko, Ringstrasse 34, 85764 Oberschleissheim, DE;
 Balling, Rudolf, Winlandstrasse 20, 81549 Muenchen, DE;
 Volz, Anja, Ringstrasse 34, 85764 Oberschleissheim, DE;
 Goeke, Burkhard, Mariborer Strasse 22, 35037 Marburg, DE;
 Wolf, Eckhard, Westendstrasse 153, 80339 Muenchen, DE

PA GSF-Forschungszentrum fuer Umwelt und Gesundheit GmbH, Ingolstaedter
Landstrasse 1, Neuherberg, 85764 Oberschleissheim, DE;
Wolf, Eckhard, Prof. Dr., Westendstrasse 153, 80339 Muenchen, DE
PAN 210878; 2816890
AG Reinhard - Skuhra - Weise & Partner, Postfach 44 01 51, 80750 Muenchen,
DE
AGN 100731
OS BEPA2000012 EP 0979872 A1 0024
SO Wila-EPZ-2000-H07-T1a
DT Patent
LA Anmeldung in Deutsch; Veroeffentlichung in Deutsch
DS R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE;
R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO;
R SI
PIT EPA1 EUROPAEISCHE PATENTANMELDUNG
PI EP 979872 A1 20000216
OD 20000216
AI EP 1999-115140 19990811
PRAI DE 1998-19836382 19980811

L1 ANSWER 13 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 978565 EUROPATFULL ED 20000227 EW 200006 FSOS
TIEN PROCESS FOR PRODUCING PEPTIDE WITH THE USE OF ACCESSORY PEPTIDE.
TIDE VERFAHREN ZUR HERSTELLUNG EINES PEPTIDS MITTELS EINES HILFSPEPTIDS.
TIFR PROCEDE DE PRODUCTION DE PEPTIDE AU MOYEN D'UN PEPTIDE ACCESSOIRE.
IN OHSUYE, Kazuhiro, 243, Takara-cho, Ohta-shi, Gunma 373-0042, JP;
YABUTA, Masayuki, 743-88, Nishimisono-cho, Tatebayashi-shi, Gunma
374-0038, JP;
SUZUKI, Yuji, 3011-1, Horigome-cho, Ashikaga-shi, Tochigi 326-0831, JP
PA SUNTORY LIMITED, 1-40, Dojimahama 2-chome, Kita-ku, Osaka-shi, Osaka
530-8203, JP
PAN 423902
AG Stoner, Gerard Patrick et al., MEWBURN ELLIS York House 23 Kingsway,
London WC2B 6HP, GB
AGN 59901
OS BEPA2000011 EP 0978565 A1 0057
SO Wila-EPZ-2000-H06-T1a
DT Patent
LA Anmeldung in Japanisch; Veroeffentlichung in Englisch;
Verfahren in Englisch
DS R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE;
R IT; R LI; R LU; R MC; R NL; R PT; R SE
PIT EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale Anmeldung)
PI EP 978565 A1 20000209
OD 20000209
AI EP 1999-901926 19990129
PRAI JP 1998-32272 19980130
RLI WO 99-JP406 990129 INTAKZ
WO 9938984 990805 INTPNR
ABEN A process for producing a peptide having a desired biological activity
via gene recombination characterized in that an accessory peptide is
added to the target peptide followed by the expression thereof. Use of
this process makes it possible to prevent agglutination in the recovery
and purification steps with the regulation of isoelectric points, to
achieve an elevated yield in ion exchange chromatography, to improve the
solubility of a fused protein in an enzymatic reaction wherein the
target peptide is expressed as the fused protein with another protein
and then liberated by enzymatic cleavage, to improve the solubility of
the target peptide in an enzymatic reaction wherein the peptide should
be enzymatically modified, etc., thus elevating the purification
efficiency and yield of the target protein. <image>

L1 ANSWER 14 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 969016 EUROPATFULL ED 20000213 EW 200001 FS OS
TIEN Glucagon-like peptide and insulintropin derivatives.
TIDE Dem Glukagon aehnliche Peptide und Insulintropin-Derivate.
TIFR Derives d'insulintropine et de peptide analogue au glucagon.
IN Andrews, Glenn C., 13 High Ridge Drive, Waterford, CT 06385, US;
Daumy, Gaston O., 19 Clark Lane, Gales Ferry, CT 06335, US;
Francoeur, Michael L., 1230 Southdown, Hillsborough, CA 94010, US;
Larson, Eric R., 162 Lantern Hill Road, Mystic, CT 06355, US
PA SCIOS INC., 2450 Bayshore Parkway, Mountain View, CA 94043, US
PAN 1614390
AG White, Martin Paul et al., Kilburn & Strode, 20 Red Lion Street, London
WC1R 4PJ, GB
AGN 74783
OS BEPA2000001 EP 0969016 A2 0016
SO Wila-EPZ-2000-H01-T1a
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI;
R LU; R NL; R PT; R SE
PIT EPA2 EUROPAEISCHE PATENTANMELDUNG
PI EP 969016 A2 20000105
OD 20000105
AI EP 1999-110184 19930414
PRAI US 1992-899073 19920615
RLI EP 646128 DIV
ABEN This invention relates to derivatives of glucagon-like peptide 1 (**GLP-1**), truncated **GLP-1**, insulintropin and truncated insulintropin which have a pl of about 4.0 or less or a pl of about 7.0 or greater. The derivatives of **GLP-1**, truncated **GLP-1**, insulintropin and truncated insulintropin within the scope of this invention are particularly suited for delivery to a mammal by iontophoresis. This invention also relates to methods for enhancing **insulin** action in a mammal with said derivatives and to pharmaceutical compositions comprising said derivatives. Further still, this invention relates to new uses of certain known derivatives of insulintropin and truncated insulintropin to enhance **insulin** action in a mammal by iontophoretic administration of such derivatives.

L1 ANSWER 15 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 933082 EUROPATFULL ED 19990815 EW 199931 FS OS
TIEN Methods of manipulation of cell differentiation.
TIDE Verfahren zur Manipulation der Zelldifferenzierung.
TIFR Procedes de manipulation de la differentiation cellulaire.
IN Artavanis-Tsakonas, Spyridon, 192 Ridgewood Avenue, Hamden, CT06517, US;
Muskavitch, Marc Alan Telander, 1308 Elliston Drive, Bloomington, IN 47401, US;
Fehon, Richard Grant Dept. Biology-KBT Yale Univ., 219 Prospect St., New Haven, CT 06511, US;
Rebay, Ilaria Dept. of Biology-KBT Yale Univ., 219 Prospect St., New Haven, CT 06511, US;
Blaumueller, Christine Marie, Dept. of Biology-KBT Yale Univ. 219 Prospect St., New Haven, CT 06511, US;
Shepard, Scott Brockewell, 50, Cutler Lane, Chestnut Hill, MA 02167, US

PA YALE UNIVERSITY, 216 Prospect Street, New Haven, CT 06511, US;
INDIANA UNIVERSITY FOUNDATION, Showalter House P.O. Box 500, Bloomington
Indiana 47402, US
PAN 479558; 473800
AG Pochart, Francois, Cabinet Hirsch, 34, rue de Bassano, 75008 Paris, FR
AGN 77351
OS ESP1999055 EP 0933082 A1 990804
SO Wila-EPZ-1999-H31-T1b
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IT; R LI; R LU;
R MC; R NL; R SE
PIT EPA1 EUROPÄISCHE PATENTANMELDUNG
PI EP 933082 A1 19990804
OD 19990804
AI EP 1999-101561 19920501
PRAI US 1991-695189 19910503
US 1991-791923 19911114
RLI EP 576623 DIV
ABEN The present invention provides methods for the manipulation of cell
differentiation comprising contacting a cell with an amount of a
toporythmic protein, or with a fragment or derivative of a first
toporythmic protein which fragment or derivative being able to bind to a
second toporythmic protein, or with an amount of an antibody or fragment
thereof containing the idiotypic thereof which binds to a toporythmic
protein, said toporythmic protein being effective to manipulate the
differentiation of the contacted cell. <image>

L1 ANSWER 16 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 930366 EUROPATFULL ED 19990801 EW 199929 FS OS
TIEN Binding domains in delta proteins.
TIDE Bindungsdomaenen des Serrate-proteins.
TIFR Domaines de liaison de la proteine serrate.
IN The designation of the inventor has not yet been filed
PA YALE UNIVERSITY, 216 Prospect Street, New Haven, CT 06511, US
PAN 479558
AG Pochart, Francois, Cabinet Hirsch, 34, rue de Bassano, 75008 Paris, FR
AGN 77351
OS ESP1999051 EP 0930366 A2 990721
SO Wila-EPZ-1999-H29-T1a
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IT; R LI; R LU;
R MC; R NL; R SE
PIT EPA2 EUROPÄISCHE PATENTANMELDUNG
PI EP 930366 A2 19990721
OD 19990721
AI EP 1999-101563 19920501
PRAI US 1991-695189 19910503
US 1991-791923 19911114
RLI EP 576623 DIV
ABEN The present invention provides substantially purified fragments of a
Delta protein as well as derivatives and analogs thereof, characterized
by the ability in vitro, when expressed on the surface of a first cell
to bind to a Notch protein, or a second Delta protein or fragment
expressed on the surface of a second cell, the nucleic acid sequences
encoding said fragments as well as vectors and recombinant cells
containing the same.

A method of producing a fragment of a Delta protein is also disclosed.

<image>

L1 ANSWER 17 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 930365 EUROPATFULL ED 19990801 EW 199929 FS OS
TIEN Binding domains in serrate protein.
TIDE Bindungsdomaenen des Serrate-Proteins.
TIFR Domaines de liaison de la proteine serrate.
IN The designation of the inventor has not yet been filed
PA YALE UNIVERSITY, 216 Prospect Street, New Haven, CT 06511, US;
INDIANA UNIVERSITY FOUNDATION, Showalter House P.O. Box 500, Bloomington
Indiana 47402, US
PAN 479558; 473800
AG Pochart, Francois, Cabinet Hirsch, 34, rue de Bassano, 75008 Paris, FR
AGN 77351
OS ESP1999051 EP 0930365 A2 990721
SO Wila-EPZ-1999-H29-T1a
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IT; R LI; R LU;
R MC; R NL; R SE
PIT EPA2 EUROPAEISCHE PATENTANMELDUNG
PI EP 930365 A2 19990721
OD 19990721
AI EP 1999-101562 19920501
PRAI US 1991-695189 19910503
US 1991-791923 19911114
RLI EP 576623 DIV
ABEN The present invention provides a substantially purified fragment of a
Serrate protein, which is characterized by the ability in vitro, when
expressed on the surface of a first cell, to bind to a Notch protein
expressed on the surface of a second cell, as well as derivatives and
analog of this fragment able to bind to a second protein selected from
the group consisting of a Notch, a Delta and a Serrate protein.

The nucleic acid sequence encoding said protein as well as vectors and
recombinant cells containing the same are described. A method of
producing a fragment of a Serrate protein is also disclosed. <image>

L1 ANSWER 18 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 926159 EUROPATFULL ED 19990711 EW 199926 FS OS
TIEN Glucagon-like peptide-1 crystals.
TIDE Kristalle von Glucagon aehnlichem Peptide-1.
TIFR Cristaux de peptide-1 de type glucagon.
IN Hoffmann, James Arthur, 4272 Woodland Streams Drive, Greenwood, Indiana
46143, US;
Hermeling, Ronald Norbert, 915 East Woodhill Drive, Indianapolis,
Indiana 46227, US;
Narasimhan, Chakravarthy, 10744 Putnam Place, Carmel, Indiana 46032, US
PA ELI LILLY AND COMPANY, Lilly Corporate Center, Indianapolis, Indiana
46285, US
PAN 204942
AG Denholm, Anna Marie et al, Eli Lilly and Company Limited, Lilly Research
Center, Erl Wood Manor, Windlesham, Surrey GU20 6PH, GB
AGN 78622
OS ESP1999047 EP 0926159 A2 990630
SO Wila-EPZ-1999-H26-T1a

DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE;
 R IT; R LI; R LU; R MC; R NL; R PT; R SE
 PIT EPA2 EUROPAEISCHE PATENTANMELDUNG
 PI EP 926159 A2 19990630
 OD 19990630
 AI EP 1998-310245 19981214
 PRAI US 1997-69728 19971216
 ABEN The invention provides individual tetragonal flat rod shaped or
 plate-like crystals of glucagon-like peptide-1 related molecules,
 processes for their preparation, compositions and methods of use. The
 crystal preparations exhibit extended time action in vivo and are useful
 for treating diabetes, obesity and related conditions.

L1 ANSWER 19 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 896538 EUROPATFULL ED 20010712 EW 200127 FS PS
 TIEN USE OF ACTIVITY INHIBITING DIPEPTIDYL PEPTIDASE IV EFFECTORS FOR
 LOWERING THE BLOOD GLUCOSE LEVEL IN MAMMALS.
 TIDE VERWENDUNG VON AKTIVITAETSMINDERNDEN EFFEKTOREN DER DIPEPTIDYL PEPTIDASE
 IV ZUR SENKUNG DES BLUTGLUKOSESPIEGELS IN SAeUGERN.
 TIFR UTILISATION D'EFFECTEURS DE LA DIPEPTIDYL PEPTIDASE IV QUI DIMINUENT SON
 ACTIVITE POUR ABAISSER LA TENEUR EN GLUCOSE DANS LE SANG CHEZ LES
 MAMMIFERES.
 IN DEMUTH, Hans-Ulrich, Hegelstrasse 14, D-06114 Halle, DE;
 ROSCHE, Fred, Benndorfer Strasse 18a, D-06184 Dieskau, DE;
 SCHMIDT, Joern, Eichendorffstrasse 2, D-06114 Halle, DE;
 PAULY, Robert, P., 2631 Fairview Crescent, Vancouver, British Columbia
 V6T 2B8, CA;
 MCINTOSH, Christopher, H., S., 605-2233 Allison Road, Vancouver, British
 Columbia V6T 1T7, CA;
 PEDERSON, Ray, A., 3876 West 23rd Avenue, Vancouver, British Columbia
 V6S 1K9, CA
 PA Probiodrug Gesellschaft fuer Arzneimittelforschung mbH, Weinbergweg 23,
 06120 Halle/Saale, DE
 PAN 2476600
 AG Forstmeyer, Dietmar, Dr. rer. nat., Dipl.-Chem. et al., Boeters & Bauer,
 Bereiteranger 15, 81541 Muenchen, DE
 AGN 77023
 OS BEPB2001028 EP 0896538 B1 0009
 SO Wila-EPS-2001-H27-T1
 DT Patent
 LA Anmeldung in Deutsch; Veroeffentlichung in Deutsch
 DS R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT;
 R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R RO; R SI
 PIT EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
 PI EP 896538 B1 20010704
 OD 19990217
 AI EP 1997-924866 19970424
 PRAI DE 1996-19616486 19960425
 RLI WO 97-DE820 970424 INTAKZ
 WO 9740832 971106 INTPNR
 REP WO 95-22326 A
 REN H.-U. DEMUTH: "Recent developments in inhibiting cysteine and serine
 protease." J. ENZYME INHIB., Bd. 3, Nr. 4, 1990, Seiten 249-278,
 XP002041620 in der Anmeldung erwaehnt T.J. KIEFFER ET AL.: "degradation
 of glucose-dependent insulinotropic polypeptide and truncated
 glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase
 IV." ENDOCRINOLOGY, Bd. 136, Nr. 8, 1995, Seiten 3585-3597, XP002041621
 DATABASE WPI Week 9217 Derwent Publications Ltd., London, GB; AN

92-132891 XP002041622 & DD296075 A (LUTHER UNIVERSITAET HALLE),
21.November 1991

L1 ANSWER 20 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 869135 EUROPATFULL ED 19981018 EW 199841 FS OS
TIEN Glucagon-like peptide-1 analogs.
TIDE Analoge des Glucagon aehnlichen Peptides-1.
TIFR Analogues de peptide de type glucagon.
IN Hoffman, James Arthur, 4272 Woodland Streams Drive, Greenwood, Indiana
46143, US
PA ELI LILLY AND COMPANY, Lilly Corporate Center, Indianapolis, Indiana
46285, US
PAN 204942
AG Denholm, Anna Marie et al, Eli Lilly and Company Limited, Lilly Research
Centre, Erl Wood Manor, Windlesham Surrey GU20 6PH, GB
AGN 78623
OS ESP1998069 EP 0869135 A1 981007
SO Wila-EPZ-1998-H41-T1a
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT;
R LI; R LU; R MC; R NL; R PT; R SE
PIT EPA1 EUROPAEISCHE PATENTANMELDUNG
PI EP 869135 A1 19981007
OD 19981007
AI EP 1998-302402 19980330
PRAI US 1997-42167 19970331
ABEN The invention provides extended-action GLP-1 based
peptides and compositions that are useful for treating diabetes and
minimize the risk of hypoglycemia.

L1 ANSWER 21 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 857483 EUROPATFULL ED 19980823 EW 199833 FS OS
TIEN Substituted aminopyridines in the treatment of glucose metabolism
disorders.
TIDE Substituierte Aminopyridine zur Behandlung von Stoerungen des
Glukosestoffwechsels.
TIFR Aminopyridines substituees dans le traitement des troubles du
metabolisme du glucose.
IN Steinberg, Mitchell Irvin, 932 Roundtable Court, Indianapolis, Indiana
46260, US;
Yakubu-Madus, Fatima Emitsel, 8704 Ray Circle, Indianapolis, Indiana
46256, US
PA ELI LILLY AND COMPANY, Lilly Corporate Center, Indianapolis, Indiana
46285, US
PAN 204942
AG Hudson, Christopher Mark et al, Eli Lilly and Company Limited, Lilly
Research Centre, Erl Wood Manor, Windlesham Surrey GU20 6PH, GB
AGN 32093
OS ESP1998054 EP 0857483 A1 980812
SO Wila-EPZ-1998-H33-T1b
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT;
R LI; R LU; R MC; R NL; R PT; R SE
PIT EPA1 EUROPAEISCHE PATENTANMELDUNG
PI EP 857483 A1 19980812

OD 19980812
 AI EP 1998-300968 19980210
 PRAI US 1997-798661 19970211
 ABEN The present invention provides a method of inhibiting glucose metabolism deterioration in a mammal by administering a substituted aminopyrimidine having the Formula <image> wherein
 R.sup1., R.sup2., and R.sup3. are, independently, hydrogen, halogen, C.sub1.-C.sub4. alkoxy, C.sub1.-C.sub4. alkylthio, C.sub1.-C.sub4. alkyl, or C.sub3.-C.sub5.-cycloalkyl;
 R.sup4. is hydrogen, formyl, acetyl, propionyl or butyryl;
 provided that R.sup1., R.sup2. and R.sup3. are not all hydrogen at the same time;
 or a pharmaceutically acceptable salt or solvate thereof.

L1 ANSWER 22 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 845036 EUROPATFULL ED 19990613 EW 199922 FS PS
 TIEN FUNCTIONAL ROLE OF ADRENOMEDULLIN (AM) AND THE GENE-RELATED PRODUCT (PAMP) IN HUMAN PATHOLOGY AND PHYSIOLOGY.
 TIDE FUNKTIONELLE ROLLE VON ADRENOMEDULLIN(AM) UND DEM GEN-VERWANDTEN PRODUKT(PAMP) IN DER MENSCHLICHEN PATHOLOGIE UND PHYSIOLOGIE.
 TIFR ROLE FONCTIONNEL DE L'ADRENOMEDULLINE (AM) ET DU PRODUIT APPARENTE A UN GENE (PAMP) EN PATHOLOGIE ET PHYSIOLOGIE CHEZ L'HOMME.
 IN CUTTITTA, Frank, 7908 Hope Valley Court, Adamstown, MD 21710, US;
 MARTINEZ, Alfredo, 1231 Otis Street, N.E., Washington, DC 20017, US;
 MILLER, Mae, Jean, 4013 Middleton Drive, Monrovia, MD 20850, US;
 UNSWORTH, Edward, J., 4414 Glenridge Street, Kensington, MD 20895, US;
 HOOK, William, 4008 Jeffry Street, Wheaton, MD 20906, US;
 WALSH, Thomas, 6006 Roosevelt Street, Bethesda, MD 20817, US;
 GRAY, Karen, 18700 Walkers Choice Drive, Gaithersburg, MD 20879, US;
 MACRI, Charles, 3302 Saul Road, Kensington, MD 20895, US
 PA THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, National Institute of Health, Office of Technology Transfer, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804, US
 PAN 304191
 AG Vossius, Volker, Dr. et al, Dr. Volker Vossius, Patentanwaltskanzlei - Rechtsanwaltskanzlei, Holbeinstrasse 5, 81679 Muenchen, DE
 AGN 12524
 OS EPB1999033 EP 0845036 B1 990602
 SO Wila-EPS-1999-H22-T1
 DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT;
 R LI; R LU; R MC; R NL; R PT; R SE
 PIT EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
 PI EP 845036 B1 19990602
 OD 19980603
 AI EP 1996-928205 19960816
 PRAI US 1995-2514 19950818
 US 1995-2936 19950830
 US 1996-13172 19960312
 RLI WO 96-US13286 960816 INTAKZ
 WO 9707214 970227 INTPNR
 REP EP 622458 A WO 94-25482 A
 REN EIGHTY-SIXTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, TORONTO, ONTARIO, CANADA, MARCH 18-22, 1995. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 36 (0). 1995. 265. ISSN: 0197-016X, XP002017893 MARTINEZ A ET AL:
 "Adrenomedullin, a new hypotensive peptide, is expressed in normal lung and in pulmonary tumors."

L1 ANSWER 23 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 750044 EUROPATFULL ED 19970307 EW 199652 FS OS
TIEN DNA constructs and transfection of cells therewith for homologous recombination.
TIDE DNA-Konstruktionen und Transfection von Zellen damit durch homologe Rekombination.
TIFR Constructions d'ADN et leur utilisation dans la transfection par recombinaison homologue de cellules.
IN Selden, Richard F., 106 Bristol Road, Wellesley, Massachusetts 02181, US;
Heartlein, Michael W., 167 Reed Farm Road, Boxborough, Massachusetts 01719, US;
Tresco, Douglas A., 87 Brantwood Road, Arlington, Massachusetts 02174, US
PA TRANSKARYOTIC THERAPIES, INC., 195 Albany Street, Cambridge, MA 02139, US
PAN 1463100
AG Holdcroft, James Gerald, Dr. et al, Graham Watt & Co., Riverhead, Sevenoaks, Kent TN13 2BN, GB
AGN 31911
OS ESP1996070 EP 0750044 A2 961227
SO Wila-EPZ-1996-H52-T1a
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R SE
PIT EPA2 EUROPAEISCHE PATENTANMELDUNG
PI EP 750044 A2 19961227
OD 19961227
AI EP 1996-202037 19921105
PRAI US 1991-787840 19911105
US 1991-789188 19911105
US 1992-911533 19920710
RLI EP 649464 DIV
ABEN The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin transfected with exogenous genetic material (DNA) which encodes a desired (e.g. a therapeutic) product or is itself a desired (e.g. therapeutic) product, methods by which primary and secondary cells are transfected to include exogenous genetic material, including DNA targeting by homologous recombination and methods of producing clonal cell strains or heterogenous cell strains.

The exogenous DNA construct comprises a targeting sequence, a regulatory sequence, an exon and a splice donor site, an intron or a splice acceptor site. A barrier device which permits the passage of the therapeutic product containing the cells and use of the cells in therapeutic applications are also included in the invention.

The exogenous DNA either encodes a product, such as a translational product (e.g. a protein) or a transcriptional product (e.g. a ribozyme or an anti-sense nucleic acid sequence) which is a therapeutic product or is itself a therapeutic product (e.g. DNA which binds to a cellular regulatory protein or alters gene expression). <image>

L1 ANSWER 24 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 733644 EUROPATFULL ED 19970307 EW 199639 FS OS

TIEN Glucagon-like insulintropic complexes, compositions and methods.
 TIDE Glucagonaehnliche, insulintrope Komplexe, ihre Zusammensetzungen und ihr Herstellungsverfahren.
 TIFR Complexes insulintropes de type glucagon, compositions les contenant et methode de preparation.
 IN Galloway, John Allison, 215 Olde Mill Cove, Indianapolis, Indiana 46260, US;
 Hoffmann, James Arthur, 4272 Woodland Streams Drive, Greenwood, Indiana 46143, US
 PA ELI LILLY AND COMPANY, Lilly Corporate Center, Indianapolis, Indiana 46285, US
 PAN 204942
 AG Tapping, Kenneth George et al, Lilly Industries Limited European Patent Operations Erl Wood Manor, Windlesham Surrey GU20 6PH, GB
 AGN 52302
 OS ESP1996051 EP 0733644 A1 960925
 SO Wila-EPZ-1996-H39-T1a
 DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R NL; R PT; R SE
 PIT EPA1 EUROPÄISCHE PATENTANMELDUNG
 PI EP 733644 A1 19960925
 OD 19960925
 AI EP 1995-303423 19950523
 PRAI US 1995-407831 19950321
 ABEN The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of *insulin* in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.

L1 ANSWER 25 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 709455 EUROPATFULL UP 19970408 EW 199618 FS OS STA R
 TIEN Monoclonal antibody to human glicentin, hybridoma for producing said antibody and assay method for human glicentin using said antibody.
 TIDE Monoklonaler Antikörper gegen menschliches Glicentin, Hybridoma zur Herstellung dieses Antikörpers und Testverfahren fuer menschliches Glicentin unter Verwendung dieses Antikörpers.
 TIFR Anticorps monoclonal dirige contre la glicentine humaine, hybridome produisant l'anticorps cite et methode d'essai pour glicentine humaine utilisant cet anticorps.
 IN Yanaihara, Noboru, c/o Yanaihara Institute Inc., 2480-1, Awakura, Fujinomiya-shi, Shizuoka-ken, JP;
 Sato, Takeya, c/o Nisshin Flour Milling Co., Ltd., Pharma. Res. Ctr., 3-1 Tsurugaoka 5-chome, Ohimachi, Iruma-gun, Saitama-ken, JP;
 Fukuchi, Kiyoshi, Nisshin Flour Milling Co., Ltd., 19-12, Nihonbashi-Koami-cho, Chuo-ku, Tokyo, JP
 PA NISSHIN FLOUR MILLING CO., LTD., 19-12, Nihonbashi-koamicho, Chuo-ku, Tokyo, JP
 PAN 300701
 AG Woods, Geoffrey Corlett et al, J.A. KEMP & CO. 14 South Square Gray's Inn, London WC1R 5LX, GB
 AGN 48721
 OS ESP1996022 EP 0709455 A1 960501
 SO Wila-EPZ-1996-H18-T1a
 DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch

DS R BE; R CH; R DE; R DK; R ES; R FR; R GB; R IT; R LI; R NL; R SE
 PIT EPA1 EUROPÄISCHE PATENTANMELDUNG
 PI EP 709455 A1 19960501
 OD 19960501
 AI EP 1995-307748 19951031
 PRAI JP 1994-266567 19941031
 JP 1995-185272 19950721

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 709455 EUROPATFULL UP 19980920 EW 199837 FS PS
 TIEN Monoclonal antibody to human glicentin, hybridoma for producing said antibody and assay method for human glicentin using said antibody.
 TIDE Monoklonaler Antikörper gegen menschliches Glicentin, Hybridoma zur Herstellung dieses Antikörpers und Testverfahren fuer menschliches Glicentin unter Verwendung dieses Antikörpers.
 TIFR Anticorps monoclonal dirige contre la glicentine humaine, hybridome produisant l'anticorps cite et methode d'essai pour glicentine humaine utilisant cet anticorps.
 IN Yanaihara, Noboru, c/o Yanaihara Institute Inc., 2480-1, Awakura, Fujinomiya-shi, Shizuoka-ken, JP;
 Sato, Takeya, c/o Nisshin Flour Milling Co., Ltd., Pharma. Res. Ctr., 3-1 Tsurugaoka 5-chome, Ohimachi, Iruma-gun, Saitama-ken, JP;
 Fukuchi, Kiyoshi, Nisshin Flour Milling Co., Ltd., 19-12, Nihonbashi-Koami-cho, Chuo-ku, Tokyo, JP
 PA NISSHIN FLOUR MILLING CO., LTD., 19-12, Nihonbashi-koamicho, Chuo-ku, Tokyo, JP
 PAN 300701
 AG Woods, Geoffrey Corlett et al, J.A. KEMP & CO. 14 South Square Gray's Inn, London WC1R 5LX, GB
 AGN 48721
 OS EPB1998050 EP 0709455 B1 980909
 SO Wila-EPS-1998-H37-T1
 DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R BE; R CH; R DE; R DK; R ES; R FR; R GB; R IT; R LI; R NL; R SE
 PIT EPB1 EUROPÄISCHE PATENTSCHRIFT
 PI EP 709455 B1 19980909
 OD 19960501
 AI EP 1995-307748 19951031
 PRAI JP 1994-266567 19941031
 JP 1995-185272 19950721
 REN DATABASE WPI Week 9310, Derwent Publications Ltd., London, GB; AN 93-079456 &
 JP-A-5023196 (NISSHIN FLOUR MILLING CO) 02 February 1993
 ABEN A monoclonal antibody to human glicentin that recognises an epitope located between positions 51 and 69, especially between positions 51 and 62, in the amino acid sequence of human glicentin is useful for assaying for human glicentin is useful for assaying for human glicentin. One such antibody is the antibody is produced by a hybridoma 3D5A (FERM BP-5214).

L1 ANSWER 26 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 708179 EUROPATFULL UP 19970408 EW 199617 FS OS STA R
 TIEN Glucagon-like insulinotropic peptide analogs, compositions, and methods of use.
 TIDE Glucagon-ae hnliche insulinotrope Peptid-Analoge, Zusammensetzungen und Verwendungsverfahren.
 TIFR Analogues de peptides insulinotropes de type glucagon, ocompositions et methode d'utilisation.
 IN Chen, Victor John, 8131 Menlo Court, East Drive, Indianapolis, Indiana

46140, US;
 Dimarchi, Richard D., 10890 Wilmington Drive, Carmel, Indiana 46033, US;
 Kriauciunas, Aidas V., 5344 Deer Creek Drive, Indianapolis, Indiana
 46254, US;
 Smiley, David L., 6468 East 200 South Road, Greenfield, Indiana 46140,
 US;
 Stucky, Russell D., 5025-7 Turtle Creek Court, Indianapolis, Indiana
 46227, US
 PA ELI LILLY AND COMPANY, Lilly Corporate Center, Indianapolis, Indiana
 46285, US
 PAN 204942
 AG Tapping, Kenneth George, Lilly Industries Limited European Patent
 Operations Erl Wood Manor, Windlesham Surrey GU20 6PH, GB
 AGN 52302
 OS ESP1996021 EP 0708179 A2 960424
 SO Wila-EPZ-1996-H17-T1a
 DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI;
 R LU; R NL; R PT; R SE
 PIT EPA2 EUROPÄISCHE PATENTANMELDUNG
 PI EP 708179 A2 19960424
 OD 19960424
 AI EP 1995-307299 19951013
 PRAI US 1994-324960 19941018
 ABEN Glucagon-like insulinotropic peptide (GLP-1(7-37))
 analogs and derivatives are disclosed. The analogs include amino acid
 substitutions, amino and carboxyl terminal modifications, and
 C.sub6.-C.sub1..sub0. acylations. The claimed compounds stimulate the
 secretion or biosynthesis of **insulin** in poorly functioning
 beta cells and are therefore useful in treating Type II diabetics

L1 ANSWER 27 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 700995 EUROPATFULL UP 19970408 EW 199611 FS OS STA R
 TIEN Process for production of protein.
 TIDE Verfahren fuer die Herstellung von Proteinen.
 TIFR Procède pour la production de proteines.
 IN Yabuta, Masayuki, 743-88, Nishimisono-cho, Tatebayashi-shi, Gunma, JP;
 Ohsuye, Kazuhiro, 243, Takara-cho, Ohta-shi, Gunma, JP
 PA SUNTORY LIMITED, 1-40, Dojimahama 2-chome, Kita-ku, Osaka-shi, Osaka, JP
 PAN 423904
 AG Stoner, Gerard Patrick et al, MEWBURN ELLIS York House 23 Kingsway,
 London WC2B 6HP, GB
 AGN 59901
 OS ESP1996014 EP 0700995 A2 960313
 SO Wila-EPZ-1996-H11-T1a
 DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI;
 R LU; R MC; R NL; R PT; R SE
 PIT EPA2 EUROPÄISCHE PATENTANMELDUNG
 PI EP 700995 A2 19960313
 OD 19960313
 AI EP 1995-306235 19950906
 PRAI JP 1994-238595 19940907
 JP 1994-296028 19941107

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 700995 EUROPATFULL UP 20010730 EW 200129 FS PS

TIEN Process for production of protein.
 TIDE Verfahren fuer die Herstellung von Proteinen.
 TIFR Procède pour la production de proteines.
 IN Yabuta, Masayuki, 743-88, Nishimisono-cho, Tatebayashi-shi, Gunma, JP;
 Ohsuye, Kazuhiro, 243, Takara-cho, Ohta-shi, Gunma, JP
 PA SUNTORY LIMITED, 1-40, Dojimahama 2-chome, Kita-ku, Osaka-shi, Osaka, JP
 PAN 423904
 AG Stoner, Gerard Patrick et al., MEWBURN ELLIS York House 23 Kingsway,
 London WC2B 6HP, GB
 AGN 59901
 OS BEPB2001030 EP 0700995 B1 0046
 SO Wila-EPS-2001-H29-T1
 DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R IE; R IT; R LI; R NL;
 R SE
 PIT EPB1 EUROPAEISCHE PATENTSCHRIFT
 PI EP 700995 B1 20010718
 OD 19960313
 AI EP 1995-306235 19950906
 PRAI JP 1994-238595 19940907
 JP 1994-296028 19941107
 REN APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 44, 1995, pages 118-125,
 XP002008703 M. YABUTA ET AL.: "Hyperproduction of a recombinant fusion
 protein of S. aureus V8 protease in E. coli and its processing by OmpT
 protease to release an active V8 protease derivative" APPLIED
 MICROBIOLOGY AND BIOTECHNOLOGY, vol. 37, 1992, pages 621-625,
 XP002008704 P.G. SEEBOTH ET AL.: "In-vitro cleavage of a fusion protein
 bound to cellulose using the soluble yscF (KEX2) variant" ENZYME MICROB.
 TECHNOL., vol. 15, 1993, pages 593-600, XP002008705 I. SUOMINEN ET AL.:
 "Enhanced revocery and purification of Aspergillus glucoamylase from S.
 cerevisiae by the addition of poly(aspartic acid) tails" EUROPEAN
 JOURNAL OF BIOCHEMISTRY, vol. 170, 1987, pages 241-246, XP002008706 C.J.
 VAN DEN BERGH ET AL.: "Secretion of biologically active porcine
 prophospholipase A2 ba S. cerevisiae" BIOTECHNOLOGY, vol. 9, 1991, pages
 378-381, XP002008707 R. CONTRERAS ET AL.: "Efficient KEX2-like
 processing of a glucoamylase-interleukin-6 fusion protein by A. nidulans
 and secretion of mature interleukin-6" MOL. GEN. GENET., vol. 233, 1992,
 pages 42-48, XP002008708 C. HANKE ET AL.: "Processing by OmpT of fusion
 proteins carrying the HlyA transport signal during secretion by the E.
 coli hemolysin transport system"
 ABEN A process for the production of a desired polypeptide comprising the
 steps of: (1) transforming host cells with an expression vector
 comprising a gene coding for a fusion protein comprising a desired
 polypeptide and a protective polypeptide; (2) culturing the transformed
 host cells so as to express said gene to produce a fusion protein; and
 (3) excising the desired polypeptide from the fusion protein with a
 protease intrinsic to the host cells. A large amount of a desired
 polypeptide can be produced at a low cost. Especially according to the
 present invention, a large amount of S. aureus V8 protease can be
 efficiently produced at low cost using a safe host as E. coli according
 to gene recombination procedures.

 L1 ANSWER 28 OF 38 EUROPATFULL COPYRIGHT 2001 WILA
 PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET
 AN 699686 EUROPATFULL ED 19970108 EW 199610 FS OS
 TIEN Biologically active fragments of glucagon-like insulinotropic peptide.
 TIDE Biologisch aktive Fragmente des Glucagon aehnlichen, insulinotropen
 Peptides.
 TIFR Fragments biologiquement actifs de peptide insalintrope de type
 glucagon.

IN Johnson, William Terry, 1367 Maynard Drive, Indianapolis, Indiana 46227, US;
 Yakubu-Madus, Fatima Emitsela, 8704 Ray Circle, Indianapolis, Indiana 46256, US
 PA ELI LILLY AND COMPANY, Lilly Corporate Center, Indianapolis, Indiana 46285, US
 PAN 204942
 AG Hudson, Christopher Mark, Lilly Industries Limited European Patent Operations Erl Wood Manor, Windlesham Surrey GU20 6PH, GB
 AGN 32091
 OS ESP1996012 EP 0699686 A2 960306
 SO Wila-EPZ-1996-H10-T1a
 DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R NL; R PT; R SE
 PIT EPA2 EUROPAEISCHE PATENTANMELDUNG
 PI EP 699686 A2 19960306
 OD 19960306
 AI EP 1995-305963 19950825
 PRAI US 1994-297731 19940830
 ABEN N-terminal truncated forms of glucagon like insulinotropic peptide (GLP-1) and analogs thereof are provided. The claimed polypeptides promote glucose uptake by cells but do not stimulate insulin expression or secretion. The invention also provides methods for treating diabetes and pharmaceutical formulations comprising the claimed polypeptides.

L1 ANSWER 29 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 658568 EUROPATFULL ED 19991212 EW 199525 FS OS STA B
 TIEN Glucagon-like insulinotropic peptides, compositions and methods.
 TIDE Glucagon-ae hnliche, insalino trope Peptide, ihre Zusammensetzungen und ihre Herstellungsverfahren.
 TIFR Peptides insulinotropes de type glucagon, compositions les contenant et methode de preparation.
 IN Galloway, John Allison, 215 Olde Mill Cove, Indianapolis, Indiana 46260, US;
 Hoffmann, James Arthur, 4272 Woodland Streams Drive, Greenwood, Indiana 46143, US
 PA ELI LILLY AND COMPANY, Lilly Corporate Center, Indianapolis Indiana 46285, US
 PAN 204942
 AG Tapping, Kenneth George et al, Lilly Industries Limited European Patent Operations Erl Wood Manor, Windlesham Surrey GU20 6PH, GB
 AGN 52301
 OS ESP1995040 EP 0658568 A1 950621
 SO Wila-EPZ-1995-H25-T1a
 DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R NL; R PT; R SE
 PIT EPA1 EUROPAEISCHE PATENTANMELDUNG
 PI EP 658568 A1 19950621
 OD 19950621
 AI EP 1994-308950 19941202
 PRAI US 1993-164277 19931209
 ABEN The present invention provides novel compounds comprising certain GLP-1 molecules complexed with a divalent metal cation, pharmaceutical compositions thereof, and methods of using such compounds for enhancing the expression of insulin in B-type

islet cells and for treating maturity onset diabetes mellitus in mammals, particularly humans.

L1 ANSWER 30 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 649464 EUROPATFULL ED 19970806 EW 199730 FS PS
TIEN TRANSFECTION OF VERTEBRATE CELLS E.G. BY HOMOLOGOUS RECOMBINATION.
TIDE TRANSFEKTION VON WIRBELTIERZELLEN BEISPIELSWEISE DURCH HOMOLOGE
REKOMBINATION.
TIFR TRANSFECTION DE CELLULES DE VERTEBRES, PAR EXEMPLE PAR RECOMBINAISON
HOMOLOGUE.
IN SELDEN, Richard, F., 106 Bristol Road, Wellesley, MA 02181, US;
HEARTLEIN, Michael, W., 167 Reed Farm Road, Boxborough, MA 01719, US;
TRECO, Douglas, A., 87 Brantwood Road, Arlington, MA 02174, US
PA TRANSKARYOTIC THERAPIES, INC., 195 Albany Street, Cambridge, MA 02139,
US
PAN 1463100
AG Holdcroft, James Gerald, Dr. et al, Graham Watt & Co., Riverhead,
Sevenoaks, Kent TN13 2BN, GB
AGN 31911
OS EPB1997048 EP 0649464 B1 970723
SO Wila-EPS-1997-H30-T1
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI;
R LU; R MC; R NL; R SE
PIT EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PI EP 649464 B1 19970723
OD 19950426
AI EP 1992-924367 19921105
PRAI US 1991-787840 19911105
US 1991-789188 19911105
US 1992-911533 19920710
RLI WO 92-US9627 921105 INTAKZ
WO 9309222 930513 INTPNR
REP EP 236059 A EP 255231 A
EP 452894 A WO 87-00201 A
WO 88-00239 A WO 88-08306 A
WO 89-01517 A WO 90-11354 A
WO 91-09955 A WO 91-13151 A
WO 91-19796 A WO 92-03917 A
WO 92-08796 A WO 92-19255 A
WO 92-20808 A WO 93-04169 A
GB 2159172 A
REN SCIENCE, Volume 236, May 1987; R F Selden et al: "Implantation of
Genetically Engineered Fibroblasts into Mice: Implications for Gene
Therapy", pages 714-718 SCIENCE, Volume 244, June 1989; Theodore
Friedmann: "Progress Toward Human Gene Therapy", pages 1275-1281
PROC.NATL.ACAD.SCI., Volume 88, September 1991; H Zheng et al, "Fidelity
of targeted recombination in human fibroblasts and murine embryonic stem
cells", pages 8067-8071 SCIENCE, Volume 244, June 1989; M R Capecchi:
"Altering the Genome by Homologous Recombination", pages 1288-1292
PROC.NATL.ACAD.SCI., Volume 86, January 1989; J M Sedivy et al:
"Positive genetic selection for gene disruption in mammalian cells by
homologous recombination", pages 230-231 SCIENCE, Volume 237, 1987; J R
Morgan et al: "Expression of an Exogenous Growth Hormone Gene by
Transplantable Human Epidermal Cells, pages 1476-1479 NUCLEIC ACIDS
RESEARCH, Volume 19, No. 14, 1991; J E Itzhaki et al: "Targeted
disruption of a human interferon-inducible gene detected by secretion of
human growth hormone", pages 3835-3842 SCIENCE, Volume 222, November
1983; R D Palmiter et al: "Metallothionein-Human GH Fusion Genes

Stimulate Growth of Mice", pages 809-814 DNA AND CELL BIOLOGY, Volume 9, No. 7, 1990; A M Sittler et al: "Tissue- Specific Expression of the Rat Growth Hormone Gene Is Due to the Interaction of Multiple Promoter, Not Enhancer, Elements", pages 511-518 Dialog Information Service, file 55, BIOSIS, Dialog accession no. 7115105, BIOSIS no. 88037850; Kramerova I A et al: "EXPRESSION OF THE CLONED HUMAN ERYTHROPOIETIN GENE IN CHO CELLS KRAMEROVA I A", BIOPOLIM KLETKA 5 (2). 1989, 47-51 Dialog Information Service, file 155, Medline, Dialog accession no. 07638459, Medline accession no. 91157459; Smith BR: "Regulation of hematopoiesis", Yale J Biol Med Sep-Oct 1990, 63 (5), pages 371-380 Dialog Information Service, file 154, Medline, Dialog accession no. 07244882, Medline accession no. 90151882; Corey C A et al, Exp Hematol Mar 1990, 18(3), pages 201-204 Dialog Information Service, file 155, Medline, Dialog accession no. 05976989, Medline accession no. 86277989; Drucker DJ et al: "Cell-specific post- translational processing of preproglucagon expressed from a metallothionein- glucagon fusion gene", J Biol Chem Jul 25 1986, 261 (21), pages 9637-9643 Dialog Information Service, file 155, Medline, Dialog accession no. 07523611, Medline accession no. 91042611; Lee YC et al: "Glucagon gene 3'-flanking sequences direct formation of proglucagon messenger RNA 3'-ends in islet and nonislet cells lines", Mol Endocrinol Jun 1990, 4 (6), pages 800-806 Bone Marrow Purging and Processing, Volume, 1990; A Keating et al: "GENE TRANSFER BY ELECTROPORATION: A MODEL FOR GENE THERAPY", pages 491-498 The Journal of Biological Chemistry, Volume 266, No. 22, August 1991; G Y Wu et al: "Receptor-mediated Gene Delivery in Vivo. PARTIAL CORRECTION OF GENETIC ANALBUMINEMIA IN NAGASE RATS", pages 14338-14342 Proc. Natl. Acad. Sci., Volume 88, May 1991; E G Shesely et al: "Correction of a human betas-globin gene by gene targeting", pages 4294-4298 Nature, Volume 336, November 1988; S L Mansour et al: "Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes", pages 348-352 MOLECULAR AND CELLULAR BIOLOGY, Volume 11, No. 6, June 1991; S D Lupton et al: "Dominant Positive and Negative Selection Using a Hygromycin Phosphotransferase-Thymidine Kinase Fusion Gene", pages 3374-3378 Biochimie, Volume 73, 1991; R Fishel et al: "Biochemical studies of homologous and nonhomologous recombination in human cells", pages 257-267 Nucleic Acids Research, Volume 18, No. 12, 1990; J P Morgenstern et al: "Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and

L1 ANSWER 31 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 631505 EUROPATFULL ED 20000109 EW 199950 FS PS
 TIEN USE OF A PEPTIDE.
 TIDE VERWENDUNG EINES PEPTIDS.
 TIFR UTILISATION D'UN PEPTIDE.
 IN EFENDIC, Suad, Stjaernvaegen 16B, S-181 34 Lindingoe, SE;
 GUTNIAK, Mark, Haesselby Strandvaeg 26, S-165 65 Haesselby, SE;
 PA KIRK, Ole, Stefansgade 38, 3/tv., DK-2200 Copenhagen N, DK
 NOVO NORDISK A/S, Novo Alle, 2880 Bagsvaerd, DK;
 EFENDIC, Suad, Stjaernvaegen 16B, S-181 34 Lindingoe, SE;
 GUTNIAK, Mark, Haesselby Strandvaeg 26, S-165 65 Haesselby, SE
 PAN 231781; 1707010; 1707030
 AG Jorgensen, Dan et al., Novo Nordisk A/S, Patent Department, Novo Alle,
 2880 Bagsvaerd, DK
 AGN 63111
 OS EPB1999067 EP 0631505 B1 991215
 SO Wila-EPS-1999-H50-T1
 DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI;
 R LU; R NL; R PT; R SE

PIT EPB1 EUROPÄISCHE PATENTSCHRIFT (Internationale Anmeldung)
 PI EP 631505 B1 19991215
 OD 19950104
 AI EP 1993-907820 19930318
 PRAI DK 1992-363 19920319
 RLI WO 93-DK99 930318 INTAKZ
 WO 9318786 930930 INTPNR
 REP WO 87-06941 A WO 90-11296 A
 WO 91-11457 A
 REN Diabetes, Vol. 40(1991): Suppl. 1, page 237A, J.C. PARKER et al.:
 "Glucagon-like Peptide 1(7-37) and Glibenclamide Stimulate Insulin
 Secretion by Different Glucose-Dependent Mechanisms"

L1 ANSWER 32 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 619322 EUROPATFULL ED 20000130 EW 199441 FS OS STA B
 TIEN Prolonged delivery of peptides.
 TIDE Verzoegerte Freigabe von Peptiden.
 TIFR Liberation prolonguee des peptides.
 IN Danley, Dennis Edward, 8, Lee Brook Drive, Ledyard, CT, 06339, US;
 Gelfand, Robert Alan, 100, Randi Drive, Madison, CT, 06443, US;
 Geoghegan, Kieran Francis, 14, Fort Rachel Place, Mystic, CT, 06355, US;
 Yesook, Kim, 47, Quarry Dock Road, Branford, CT, 06405, US;
 Lambert, William Joseph, 17, Spring Rock Road, East Lyme, CT, 06333, US;
 Hong, Qi, 290, Meridian Street, Unit 1, Groton, CT, 06340, US
 PA PFIZER INC., 235 East 42nd Street, New York, N.Y. 10017, US
 PAN 200961
 AG Bradbrook, Geoffrey William et al, PFIZER LIMITED Ramsgate Road,
 Sandwich Kent, CT13 9NJ, GB
 AGN 28593
 OS ESP1994072 EP 0619322 A2 941012
 SO Wila-EPZ-1994-H41-T1a
 DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI;
 R LU; R NL; R PT; R SE
 PIT EPA2 EUROPÄISCHE PATENTANMELDUNG
 PI EP 619322 A2 19941012
 OD 19941012
 AI EP 1994-300981 19940210
 PRAI US 1993-44133 19930407
 ABEN There are disclosed methods for the treatment of non-insulin
 dependent diabetes mellitus in a mammal comprising the prolonged
 administration of GLP-1(7-37), and related
 peptides. Also disclosed are compositions to prolong the administration
 of the peptides.

L1 ANSWER 33 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 599303 EUROPATFULL ED 20000213 EW 199422 FS OS STA B
 TIEN Peptide conjugate.
 TIDE Peptide-Konjugate.
 TIFR Conjugues peptidiques.
 IN Fukuta, Makoto, 2-10-B-508, Tsurumainishi-machi, Nara, Nara 631, JP;
 Iinuma, Satoshi, 1-1-308, Dohshodai 1-chome, Suma-ku, Kobe, Hyogo 654,
 JP;
 Okada, Hiroaki, 44-11-704, Yamadaminami, Suita, Osaka 565, JP
 PA TAKEDA CHEMICAL INDUSTRIES, LTD., 1-1, Doshomachi 4-chome, Chuo-ku,
 Osaka 541, JP

PAN 204706
AG von Kreisler, Alek, Dipl.-Chem. et al, Patentanwaelte von Kreisler, Selting, Werner, Bahnhofsvorplatz 1 (Deichmannhaus), D-50667 Koeln, DE
AGN 12437
OS ESP1994038 EP 0599303 A2 940601
SO Wila-EPZ-1994-H22-T1b
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R NL; R PT; R SE
PIT EPA2 EUROPAEISCHE PATENTANMELDUNG
PI EP 599303 A2 19940601
OD 19940601
AI EP 1993-118961 19931125
PRAI JP 1992-318031 19921127
ABEN The present invention provides a conjugate capable of passing the blood-brain barrier comprising a bioactive peptide or protein incapable of passing the blood-brain barrier and a carrier peptide which exhibits substantially no bioactivity and which is capable of passing the blood-brain barrier. The conjugate makes it possible to allow a bioactive peptide or protein incapable of passing the blood-brain barrier to easily pass the blood-brain barrier for uniform transport to the brain without any side effect of the carrier peptide.

L1 ANSWER 34 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 587255 EUROPATFULL ED 20000227 EW 199411 FS OS STA B
TIEN Insulinotropic hormone.
TIDE Insulinotropische Hormone.
TIFR Hormone insulinotropique.
IN Habener, Joel, 217 Plymouth Road, Newton Highlands, Massachusetts 02161, US
PA THE GENERAL HOSPITAL CORPORATION, 55 Fruit Street, Boston, MA 02114, US
PAN 370400
AG Wright, Simon Mark et al, Kilburn & Strobe 30 John Street, London WC1N 2DD, GB
AGN 72651
OS ESP1994017 EP 0587255 A1 940316
SO Wila-EPZ-1994-H11-T1a
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R FR; R GB; R IT; R LI; R LU; R NL; R SE
PIT EPA1 EUROPAEISCHE PATENTANMELDUNG
PI EP 587255 A1 19940316
OD 19940316
AI EP 1993-203087 19870505
PRAI US 1986-859928 19860505
RLI EP 305387 DIV
ABEN A fragment of glucagon-like peptide I (GLP-1) has been found to be an insulinotropic hormone. This insulinotropic hormone comprises amino acid residues 7-37 of GLP-1. The insulinotropic hormone is useful as a potential therapy for Diabetes Mellitus.

L1 ANSWER 35 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 586812 EUROPATFULL ED 20000213 EW 199411 FS OS STA B
TIEN Medicaments comprising glicentin as active ingredient.

TIDE Arzneimittel, die Glicentin als aktiven Wirkstoff enthalten.
 TIFR Medicaments contenant de la glicentin comme ingredient actif.
 IN Ohneda, Akira, 4-31, Odawara 7-chome, Aoba-ku, Sendai-shi, Miyagi-ken, JP;
 Sasaki, Kazuyuki, 3-7-404, Hikarigaoka 7-chome, Nerima-ku, Tokyo, JP;
 Natori, Yohei, 7-23, Fujimidai 3-chome, Nerima-ku, Tokyo, JP;
 Nagasaki, Tomohisa, 34-21-601, Funado 2-chome, Itabashi-ku, Tokyo, JP
 PA NISSHIN FLOUR MILLING CO., LTD., 19-12, Nihonbashi-koami-cho, Chuo-ku, Tokyo 103, JP
 PAN 300700
 AG Tuerk, Gille, Hrabal, Leifert, Brucknerstrasse 20, D-40593 Duesseldorf, DE
 AGN 100971
 OS ESP1994017 EP 0586812 A2 940316
 SO Wila-EPZ-1994-H11-T1b
 DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R BE; R CH; R DE; R DK; R FR; R GB; R IT; R LI; R NL; R SE
 PIT EPA2 EUROPAEISCHE PATENTANMELDUNG
 PI EP 586812 A2 19940316
 OD 19940316
 AI EP 1993-110400 19930630
 PRAI JP 1992-185066 19920713

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 586812 EUROPATFULL ED 20000213 EW 200001 FS PS
 TIEN Medicaments comprising glicentin as active ingredient.
 TIDE Arzneimittel die Glicentin als aktiven Wirkstoff enthalten.
 TIFR Medicaments contenant de la glicentin comme ingredient actif.
 IN Ohneda, Akira, 4-31, Odawara 7-chome, Aoba-ku, Sendai-shi, Miyagi-ken, JP;
 Sasaki, Kazuyuki, 3-7-404, Hikarigaoka 7-chome, Nerima-ku, Tokyo, JP;
 Natori, Yohei, 7-23, Fujimidai 3-chome, Nerima-ku, Tokyo, JP;
 Nagasaki, Tomohisa, 34-21-601, Funado 2-chome, Itabashi-ku, Tokyo, JP
 PA NISSHIN FLOUR MILLING CO., LTD., 19-12, Nihonbashi-koami-cho, Chuo-ku, Tokyo 103, JP
 PAN 300700
 AG Tuerk - Gille - Hrabal - Struck, Patentanwaelte - European Patent Attorneys, Brucknerstrasse 20, 40593 Duesseldorf, DE
 AGN 100971
 OS BEPB2000001 EP 0586812 B1 0007
 SO Wila-EPS-2000-H01-T1
 DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R BE; R CH; R DE; R DK; R FR; R GB; R IT; R LI; R NL; R SE
 PIT EPB1 EUROPAEISCHE PATENTSCHRIFT
 PI EP 586812 B1 20000105
 OD 19940316
 AI EP 1993-110400 19930630
 PRAI JP 1992-185066 19920713
 REP WO 90-11296 A
 REN CHEMICAL ABSTRACTS, vol. 105, no. 17, 27 October 1986, Columbus, Ohio, US; abstract no. 146676h, OHNEDA A. ET AL. 'Effect of glicentin-related peptides on glucagon secretion in anesthetized dogs' page 115; & DIABETOLOGICA, vol.29, no.6, 1986 pages 397 - 401 CHEMICAL ABSTRACTS, vol. 94, no. 7, 16 February 1981, Columbus, Ohio, US; abstract no. 41670c, AHREN B. ET AL. 'Effects of glicentine on insulin secretion' page 69; & HORM. METAB. RES., vol.12, no.11, 1980 pages 582 - 586 FEBS LETTERS, vol.211, no.2, January 1987, AMSTERDAM NL pages 169 - 174 HOLST ET AL. 'Truncated glucagon-like peptide I, an insulin-releasing hormon from the distal gut'
 ABEN Agents for stimulating insulin secretion and for treating diabetes which comprise glicentin as an active ingredient.

L1 ANSWER 36 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 586657 EUROPATFULL ED 19990926 EW 199937 FS PS
TIEN RECEPTOR FOR THE GLUCAGON-LIKE-PEPTIDE-1 (GLP-1).
TIDE RECEPTOR FÜR DAS GLUCAGON ÄHNLICHES PEPTID-1 (GLP-1).
TIFR RECEPTEUR DESTINE AU PEPTIDE 1 DE TYPE GLUCAGON (GLP-1).
IN Thorens, Bernard, Dr., 70, Grand Chemin, CH-1066 Epalinges, CH
PA NOVO NORDISK A/S, Novo Alle, 2880 Bagsvaerd, DK
PAN 231781
OS EPB1999053 EP 0586657 B1 990915
SO Wila-EPS-1999-H37-T1
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IT; R LI; R LU;
R NL; R SE
PIT EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PI EP 586657 B1 19990915
OD 19940316
AI EP 1993-906589 19930323
PRAI DK 1992-398 19920325
RLI WO 93-EP697 930323 INTAKZ
WO 9319175 930930 INTPNR
REN PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 89, no. 18,
15 September 1992, WASHINGTON US pages 8641 - 8645 THORENS B;
'Expression cloning of the pancreatic beta cell receptor for the
gluco-incretin hormone glucagon-like peptide 1.' FEBS LETTERS. vol. 267,
no. 1, July 1990, AMSTERDAM NL pages 78 - 80 Richter G; Goke R; Goke
B; Arnold R; 'Characterization of receptors for glucagon-like
peptide-1(7-36)amide on rat lung membranes.' FEBS LETTERS. vol. 262, no.
1, March 1990, AMSTERDAM NL pages 139 - 141 UTTENTHAL, L.O. ET AL;
'Characterization of high-affinity receptors for truncated glucagon-like
peptide-1 in rat gastric glands.'

L1 ANSWER 37 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 512042 EUROPATFULL ED 19980426 EW 199815 FS PS
TIEN GLP-1 ANALOGS USEFUL FOR DIABETES TREATMENT.
TIDE GLP-1-ANALOGA VERWENDBAR IN DER DIABETESBEHANDLUNG.
TIFR ANALOGUES DE GLP-1 UTILES DANS LE TRAITEMENT DU
DIABETE.
IN BUCKLEY, Douglas I., 215 Brookwood Road, Woodside, CA 94062, US;
HABENER, Joel F., 156 Grant Avenue, Newton Centre, MA 02159, US;
MALLORY, Joanne B., 7 Imperial Lane, Chestnut Ridge, N.Y. 10977, US;
MOJSOV, Svetlana, 450 East 63rd Street, Apt. 3E, New York, N.Y. 10021,
US
PA BUCKLEY, Douglas I., 215 Brookwood Road, Woodside, CA 94062, US;
HABENER, Joel F., 156 Grant Avenue, Newton Centre, MA 02159, US;
MALLORY, Joanne B., 7 Imperial Lane, Chestnut Ridge, N.Y. 10977, US;
MOJSOV, Svetlana, 450 East 63rd Street, Apt. 3E, New York, N.Y. 10021,
US
PAN 1402020; 1402080; 1402040; 1402090
AG Goldin, Douglas Michael et al, J.A. KEMP & CO. 14 South Square Gray's
Inn, London WC1R 5LX, GB
AGN 31062
OS EPB1998018 EP 0512042 B1 980408
SO Wila-EPS-1998-H15-T1

DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IT; R LI; R LU;
 R NL; R SE
 PIT EPB1 EUROPÄISCHE PATENTSCHRIFT (Internationale Anmeldung)
 PI EP 512042 B1 19980408
 OD 19921111
 AI EP 1991-903738 19910124
 PRAI US 1990-468736 19900124
 RLI WO 91-US500 910124 INTAKZ
 WO 9111457 910808 INTPNR
 REN WO-A-87/06941 ENDOCRINOLOGY, vol. 126, no. 4, 1990; D. GEFEL et al., pp.
 2164-2168

L1 ANSWER 38 OF 38 EUROPATFULL COPYRIGHT 2001 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 464022 EUROPATFULL ED 20000611 EW 200022 FS PS
 TIEN INSULINOTROPIC HORMONE.
 TIDE INSULINOTROPES HORMON.
 TIFR HORMONE INSULINOTROPE.
 IN HABENER, Joel, F., 217 Plymouth Road, Newton Highlands, MA 02161, US
 PA THE GENERAL HOSPITAL CORPORATION, Fruit Street, Boston, MA 02114, US
 PAN 370401
 AG Sheard, Andrew Gregory et al., Kilburn & Strode 20 Red Lion Street,
 London WC1R 4PJ, GB
 AGN 50962
 OS BEPB2000030 EP 0464022 B1 0026
 SO Wila-EPS-2000-H22-T1
 DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R AT; R BE; R CH; R DE; R FR; R GB; R IT; R LI; R LU; R NL; R SE
 PIT EPB1 EUROPÄISCHE PATENTSCHRIFT (Internationale Anmeldung)
 PI EP 464022 B1 20000531
 OD 19920108
 AI EP 1989-910254 19890320
 RLI WO 89-US1121 890320 INTAKZ
 WO 9011296 901004 INTPNR
 REP EP 44168 A WO 87-06941 A
 REN THE LANCET, 5th December 1987, pages 1300-1303; B. KREYMAN et al.:
 "Glucagon-like peptide-1 7-36: A physiological incretin in man" GLUCAGON
 AND RELATED PEPTIDES PROCEEDINGS OF INTERNATIONAL SYMPOSIUM, Osaka, 15th
 - 16th July 1988, Editors S. TARUI et al.; & BIOMEDICAL RESEARCH, vol.
 9, supplement 3, 1988, pages 201-206; "R. KOMATSU et al.: "Effect of
 glucagon-related peptides on rat endocrine pancreas" DIABETOLOGIA,
 Volume 27, issued 1984, (GHIGLIONE et al.), "How GLUCAGON-Like is
 GLUCAGON-Like, peptide-1", Pages 599-600, See page 600 in particular.
 NATURE, Volume 302, issued 21 April 1983, (BELL et al.), "Hamster
 Preproglucagon contains the sequence of Glucagon and two related
 peptides", pages 716-718, See Fig. 1 in particular. DIABETOLOGIA, Volume
 28, issued 1985, (SCHMIDT et al.), "Glucagon-Like peptide-1 but not
 Glucagon-Like peptide-2 stimulates insulin release from isolated rat
 pancreatic islets", pages 704-707, See the summary and pages 706, 707 in
 particular. THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, Volume
 61, issued 1985, (UTTENTHAL et al.), "Molecular forms of Glucagon-like
 peptide-1 in human pancreas and Glucagonomas", pages 472-479. See the
 Abstract in particular. THE JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 260,
 issued 10 April 1985, (ANDREWS et al.), "Isolation and structures of
 Glucagon and Glucagon-like peptide from catfish pancreas", pages
 3910-3914. See Fig. 7 in particular

s Habener, Joel F./AU
3 HABENER/AU
1428 JOEL/AU
51440 F/AU
L2 2 HABENER, JOEL F./AU
((HABENER(S)JOEL(S)F)/AU)

=> d ab ibib 1-2

L2 ANSWER 1 OF 2 EUROPATFULL COPYRIGHT 2001 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 512042 EUROPATFULL EW 199815 FS PS
TITLE: GLP-1 ANALOGS USEFUL FOR DIABETES TREATMENT.
GLP-1-ANALOGA VERWENDBAR IN DER DIABETESBEHANDLUNG.
ANALOGUES DE GLP-1 UTILES DANS LE TRAITEMENT DU DIABETE.
INVENTOR(S): BUCKLEY, Douglas I., 215 Brookwood Road, Woodside, CA
94062, US;
HABENER, Joel F., 156
Grant Avenue, Newton Centre, MA 02159, US;
MALLORY, Joanne B., 7 Imperial Lane, Chestnut Ridge,
N.Y. 10977, US;
MOJSOV, Svetlana, 450 East 63rd Street, Apt. 3E, New
York, N.Y. 10021, US
PATENT ASSIGNEE(S): BUCKLEY, Douglas I., 215 Brookwood Road, Woodside, CA
94062, US;
HABENER, Joel F., 156 Grant Avenue, Newton Centre, MA
02159, US;
MALLORY, Joanne B., 7 Imperial Lane, Chestnut Ridge,
N.Y. 10977, US;
MOJSOV, Svetlana, 450 East 63rd Street, Apt. 3E, New
York, N.Y. 10021, US
PATENT ASSIGNEE NO: 1402020; 1402080; 1402040; 1402090
AGENT: Goldin, Douglas Michael et al, J.A. KEMP & CO. 14 South
Square Gray's Inn, London WC1R 5LX, GB
31062
AGENT NUMBER: EPB1998018 EP 0512042 B1 980408
OTHER SOURCE: Wila-EPS-1998-H15-T1
SOURCE: Patent
DOCUMENT TYPE: Anmeldung in Englisch; Veroeffentlichung in Englisch
LANGUAGE: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R
DESIGNATED STATES: IT; R LI; R LU; R NL; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale
Anmeldung)
PATENT INFORMATION:
PATENT NO KIND DATE

'OFFENLEGUNGS' DATE: EP 512042 B1 19980408
APPLICATION INFO.: 19921111
PRIORITY APPLN. INFO.: EP 1991-903738 19910124
RELATED DOC. INFO.: US 1990-468736 19900124
WO 91-US500 910124 INTAKZ
WO 9111457 910808 INTPNR
REF. NON-PATENT-LIT.: WO-A-87/06941 ENDOCRINOLOGY, vol. 126, no. 4, 1990; D.
GEFEL et al., pp. 2164-2168

L2 ANSWER 2 OF 2 EUROPATFULL COPYRIGHT 2001 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 464022 EUROPATFULL EW 200022 FS PS
TITLE: INSULINOTROPIC HORMONE.
INSULINOTROPES HORMON.

INVENTOR(S): HORMONE INSULINOTROPE.
 HABENER, Joel, F., 217
 Plymouth Road, Newton Highlands, MA 02161, US
 PATENT ASSIGNEE(S): THE GENERAL HOSPITAL CORPORATION, Fruit Street, Boston,
 MA 02114, US
 PATENT ASSIGNEE NO: 370401
 AGENT: Sheard, Andrew Gregory et al., Kilburn & Strode 20 Red
 Lion Street, London WC1R 4PJ, GB
 AGENT NUMBER: 50962
 OTHER SOURCE: BEPB2000030 EP 0464022 B1 0026
 SOURCE: Wila-EPS-2000-H22-T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R DE; R FR; R GB; R IT; R LI; R LU; R
 NL; R SE
 PATENT INFO.PUB.TYPE: EPB1 EUROPÄISCHE PATENTSCHRIFT (Internationale
 Anmeldung)
 PATENT INFORMATION:

	PATENT NO	KIND	DATE
'OFFENLEGUNGS' DATE:	EP 464022	B1	20000531
APPLICATION INFO.:			19920108
RELATED DOC. INFO.:	EP 1989-910254		19890320
	WO 89-US1121	890320	INTAK2
	WO 9011296	901004	INTPNR
REFERENCE PAT. INFO.:	EP 44168 A	WO 87-06941	A
REF. NON-PATENT-LIT.:	THE LANCET, 5th December 1987, pages 1300-1303; B. KREYMAN et al.: "Glucagon-like peptide-1 7-36: A physiological incretin in man" GLUCAGON AND RELATED PEPTIDES PROCEEDINGS OF INTERNATIONAL SYMPOSIUM, Osaka, 15th - 16th July 1988, Editors S. TARUI et al.; & BIOMEDICAL RESEARCH, vol. 9, supplement 3, 1988, pages 201-206; "R. KOMATSU et al.: "Effect of glucagon-related peptides on rat endocrine pancreas" DIABETOLOGIA, Volume 27, issued 1984, (GHIGLIONE et al.), "How GLUCAGON-Like is GLUCAGON-Like, peptide-1", Pages 599-600, See page 600 in particular. NATURE, Volume 302, issued 21 April 1983, (BELL et al.), "Hamster Preproglucagon contains the sequence of Glucagon and two related peptides", pages 716-718, See Fig. 1 in particular. DIABETOLOGIA, Volume 28, issued 1985, (SCHMIDT et al.), "Glucagon-Like peptide-1 but not Glucagon-Like peptide-2 stimulates insulin release from isolated rat pancreatic islets", pages 704-707, See the summary and pages 706, 707 in particular. THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, Volume 61, issued 1985, (UTTENTHAL et al.), "Molecular forms of Glucagon-like peptide-1 in human pancreas and Glucagonomas", pages 472-479. See the Abstract in particular. THE JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 260, issued 10 April 1985, (ANDREWS et al.), "Isolation and structures of Glucagon and Glucagon-like peptide from catfish pancreas", pages 3910-3914. See Fig. 7 in particular		

=>